Sino-American biotech BeyondSpring (Nasdaq: BYSI) has presented data from several studies of its lead asset plinabulin at the 2018 ASCO-SITC symposium.
Study 105
The presentation provided data from the Phase II portion of Study 105, which is investigating the candidate’s potential to prevent docetaxel chemotherapy-induced neutropenia (CIN).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze